Company List
AstraZeneca Drug List1
| S.No. | Company Name | Short Description | No of Drugs | Company Drug Price | Action | |
|---|---|---|---|---|---|---|
| 1 | AstraZeneca | AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory and Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. | 5 | 60.00 | BUY | Your Query |
| S.No. | Updated On | Drug | Price in USD | Action | ||
|---|---|---|---|---|---|---|
| 1 | Mar, 2020 | Lynparza Drug Sales & Forecast AstraZeneca drug Lynparza became the world’s ¬first approved PARP inhibitor in 2014. Initially indicated for the treatment of ovarian cancer, in 2017, .... | 20.00 | READ | BUY | Your Query |
| 2 | Mar, 2020 | Imfinzi Drug Sales & Forecast AstraZeneca drug Imfinzi is approved for lung and bladder cancer in 2017. Imfinzi, a human mAb that binds to PD-L1 and blocks the interaction of PD-L1 wit.... | 20.00 | READ | BUY | Your Query |
| 3 | Mar, 2020 | Crestor Drug Sales & Forecast AstraZeneca drug Crestor is approved in more than 115 countries for the treatment of dyslipidaemia and hypercholesterolaemia. MNG Tracker report title “.... | 20.00 | READ | BUY | Your Query |
| 4 | Mar, 2020 | Tagrisso Drug Sales & Forecast AstraZeneca drug Tagrisso is approved for lung cancer in 2015. Tagrisso is a best-in-class, highly selective, irreversible inhibitor of the activating sen.... | 20.00 | READ | BUY | Your Query |
| 5 | Mar, 2020 | Brilinta/Brilique Drug Sales & Forecast Brilinta/Brilique (ticagrelor) is an oral antiplatelet for acute coronary syndromes (ACS). Brilinta/Brilique, one of AstraZeneca Growth Platforms, is an o.... | 20.00 | READ | BUY | Your Query |
